Related Experiment Video
Updated: Apr 22, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine
Shin Ono1, Yutaro Suzuki, Naoki Fukui
1From the Dept. of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Abstract:
Association between gastric inhibitory polypeptide receptor polymorphism, rs10423928, and body mass index in olanzapine-treated schizophrenia was examined. Body mass index change for the A/T+A/A genotypes was significantly higher than that for the T/T genotype. rs10423928 may predict weight gain in schizophrenia.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Psychosis and Antipsychotic Drugs: Overview

